Patent focus on agents affecting cardiovascular and renal functions November 1999 - March 2000

Bibliography

• LUSCHER TF, OEMER BS, YANG Z, NOLL G: Molecular and cellular mechanisms of arteriosclerosis and restenosis: possibilities of gene therapy. Z. Kardiol (1996) 85(7):495–508.
   PubMedGoogle Scholar
• REDWOOD S, MARBER M, JACKSON G: Glycoprotein Ilb/Illa antagonists: do they have a role in the manage-ment of unstable angina? Int. J. Clin. Pract (1999) 53 (8) :618–622.
   Google Scholar
• •This article summarizes the studies with GP IIb/IIIa antagonists.
   Google Scholar
• KLEIMAN NS, LINCOFF AM, FLAKER GC et al: Early percutaneous coronary intervention, platelet inhibi-tion with eptifibatide and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investiga-tors. Circulation (2000) 1O1(7):751–757.
   Google Scholar
• MADAN M, BERKOWITZ SD: Understanding thrombocy-topenia and antigenicity with glycoprotein lib-Illa inhibitors. Am. Heart. J. (1999) 138(4 Pt 2):317–326.
   Google Scholar
• INGALL AH, DIXON J, BAILEY A et al.: Antagonists of the platelet P2T receptor: a novel approach to antithrom-botic therapy. J Med. Chem. (1999) 42(2):213–220.
   PubMed Web of Science ®Google Scholar
• •Presentation of a new target for regulation of blood coagulation.
   Google Scholar
• WILSON JM, FERGUSON JJ 3rd: Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin. Cardiol. (1999) 22(11):687–698.
   PubMed Web of Science ®Google Scholar
• TRUMEL C, PAYRASTRE B, PLANTAVID M et al.: A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR-1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood (1999) 94(12):4156–4165.
   PubMed Web of Science ®Google Scholar
• •New approach to role of ADP-receptors in blood coagulation.
   Google Scholar
• COUGHLIN SR: How the protease thrombin talks to cells,. Proc. Natl. Acad. Sci. USA (1999) 96(20):11023–11027.
   PubMed Web of Science ®Google Scholar
• CERUSO MA, McCOMSEY DF, LEO GC et al.: Thrombin receptor-activating peptides (TRAPs): investigation of bioactive conformations via structure-activity, spectroscopic and computational studies. Bioorg. Med.. Chem. (1999) 7(10:2353–2371.
   PubMedGoogle Scholar
• ANDRADE-GORDON P, MARYANOFF BE, DERIAN CK et al: Design, synthesis and biological characterization of a peptide-mimetic antagonist for tethered-ligand receptor. Proc. Natl. Acad. Sci. USA (1999) 96(22):12257–12262.
   PubMed Web of Science ®Google Scholar
• ••Role of PARs in coagulation is discussed.
   Google Scholar
• KAUFMANN R, PATT S, ZIEGER M et al: The two-receptor system PAR-1/PAR-4 mediates alpha-thrombin-induced [Ca2]w mobilization in human astrocytoma cells. J. Cancer. Res. Clin. Oncol. (2000) 126(2)91–94.
   Google Scholar
• CHOW TW, HELLUMS JD, THIAGARAJAN P: Thrombin receptor activating peptide (SWIM potentiates shear-induced platelet microvesiculation. J. Lab. Clin. Med. (2000) 135(0:66–72.
   PubMedGoogle Scholar
• FAREED J, LEWIS BE, CALLAS DD, HOPPENSTEADT DA, WALENGA JM, BICK RL: Antithrombin agents: a new class of anticoagulant and antithrombotic drugs. Clin. Appl. Thromb. Hemost. (1999) 5\(Suppl. 0:545–55.
   Google Scholar
• •Thrombin inhibitors are discussed as alternatives to heparin.
   Google Scholar
• KATO Y, KITA Y, NISHIO M et al: In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur. J. Pharmacol. (1999) 384 (2-3):197–202.
   PubMed Web of Science ®Google Scholar
• AL-OBAIDI MK, PHILIPPOU H, STUBBS PJ et al.: Relation-ships between homocysteine, Factor VIIa and thrombin generation in acute coronary syndromes. Circulation (2000) 101(4)372–377.
   Google Scholar
• •Explanation for the prothrombotic of homocysteine.
   Google Scholar
• SPENCER FA, BALL SP, ZHANG Q, LIU L, BENOIT S,BECKER RC: Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by Factor Xa neutralization. J. Thromb. Thrombolysis (2000) 9(3):223–228.
   PubMed Web of Science ®Google Scholar
• SCHOMIG A, HAASS M, RICHARDT G: Catecholamine release and arrhythmias in acute myocardial ischaemia. Eur. Heart J. (1991) 12 (Suppl. F):38–47.
   Google Scholar
• •Good overview about mechanisms involved in ischaemia-induced ventricular fibrillation.
   Google Scholar
• SIFFERT W, DUSING R: Sodium-proton exchange and primary hypertension. An update. Hypertension (1995) 26(4):649–655.
   PubMed Web of Science ®Google Scholar
• CHEN YF, YANG RH, MENG QC, CRAGOE EJ, JR., OPARIL S: Sodium-proton (Na±/I-1-9 exchange inhibition increases blood pressure in spontaneously hyperten-sive rat. Am. J. Med. Sci. (1994) 308(3):145–151.
   Google Scholar
• HORVAT B, TAHERI S, SALIHAGIC A: Tumour cell prolif-eration is abolished by inhibitors of Neill+ and 11CO3-/C1- exchange. Eur. J. Cancer (1 9 9 2) 29A(1):132–137.
   Google Scholar
• MOLDERINGS GJ, LIKUNGU J, GOTHERT M: N-type calcium channels control sympathetic neurotransmis-sion in human heart atrium. Circulation (2000) 101(4)403–407.
   Google Scholar
• VAN DER LEE R, PFAFFENDORF M, DE MEY JG, VAN ZWIETEN PA: Inhibitory effect of mibefradil on contractions induced by sympathetic neurotrans-mitter release in the rat tail artery. Naunyn Schmiede-bergs Arch. Pharmacol. (2000) 361 (1):74–79.
   PubMed Web of Science ®Google Scholar
• COURTEMANCHE M, RAMIREZ RJ, NATTEL S: Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. (1999) 42(2)477–489.
   Google Scholar
• SCHAFFER P, PELZMANN B, BERNHART E et al.: Estima-tion of outward currents in isolated human atrial myocytes using inactivation time course analysis. Pflugers Arch. (1998) 436(3)457–468.
   Google Scholar
• KIM S, IWAO H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. (2000) 52(0:11–34.
   PubMedGoogle Scholar
• ••A thorough review on angiotensin II-mediated effects.
   Google Scholar
• BURNIER M, BRUNNER HR: Angiotensin II receptor antagonists,. Lancet (2000) 355 (9204):637–645.
   PubMed Web of Science ®Google Scholar
• •ACE-inhibitors and angiotensin II receptor antagonists: advantages of both groups are discussed.
   Google Scholar
• GRAY GA, BATTISTINI B, WEBB DJ: Endothelins are potent, vasoconstrictors and much more besides. Trends Pharmacol. Sci. (2000) 21(2)38–40.
   Google Scholar
• ••Concise overview about endothelins.
   Google Scholar
• SATO K, MORIO Y, MORRIS KG, RODMAN DM, McMURTRY IF: Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) 278(3)1434–L442.
   Google Scholar
• MATSUHISA A, TANIGUCHI N, KOSHIO H, YATSU T, TANAKA A: Nonpeptide arginine vasopressin antago-nists for both VlA and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydro imidazol[4,5-d][1]benzoazepine-6-carbonyl) benzanilide derivatives and 4'-(5,6-dihydro-411-thiaz ol o [5,4- cl] [1]b e nz o az e p ine - 6- carb ony benzanilide derivatives. Chem. Pharm. Bull. (Tokyo) (2000) 48(0:21–31.
   PubMedGoogle Scholar
• KODAMA K, ADACHI H: Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol Exp. Ther. (1999) 290 (2) 748–752.
   PubMed Web of Science ®Google Scholar
• HANASATO N, OKA M, MURAMATSU M, NISHINO M, ADACHI H, FUKUCHI Y: E-4010, a selective phosphodi-esterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol. (1 9 9 9) 2 77(2Pt1)1225–232.
   Google Scholar
• KAKKO S, TAMMINEN M, PAIVANSALO M et al.: Choles-terol ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men. Eur. J. Clin. Invest. (2000) 30 (0 :18–25.
   PubMedGoogle Scholar
• BURNETT JR, WILCOX LI HUFF MW: Acyl coenzyme A:cholesterol acyltransferase inhibition and hepatic apolipoprotein B secretion. Clin. Chim. Acta (1999) 286(1–2)231–242.
   Google Scholar
• ACCAD M, SMITH SJ, NEWLAND DL et al.: Massive xanthomatosis and altered composition of atheroscle-rotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. J. Clin. Invest. (2000) 105(6)711–719.
   Google Scholar
• KADO S, NAGATA N: Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selection in patients with Type 2 diabetes mellitus. Diabetes Res. Gin. Pract. (1999) 46(2):143–148.
   PubMed Web of Science ®Google Scholar
• AKASAKA Y, ISHIKAWA Y, ONO I et al.: Enhanced expression of caspase-3 in hypertrophic scars and keloid: induction of caspase-3 and apoptosis in keloid fibroblasts in vitro. Lab. Invest. (2000) 80(3)345–357.
   Google Scholar
• FREUDENTHALER SM, SCHREEB K, KORNER T, GLEITER CH: Angiotensin II increases erythropoietin produc-tiion in healthy human volunteers. Eur. J. Clin. Invest. (1999) 29(10816–823.
   Web of Science ®Google Scholar
• WILDHIRT SM, SUZUKI H, HORSTMAN D et al.: Selective modulation of inducible nitric oxide synthase isoenzyme in myocardial infarction. Circulation (1997) 96(5):1616–1623.
   PubMed Web of Science ®Google Scholar
• KOJDA G, KOTTENBERG K: Regulation of basal myocar-dial function by NO. Cardiovasc. Res. (1999) 41(3):514–523.
   PubMed Web of Science ®Google Scholar
• ••Good overview about the influence of NO on myocardialfunction.
   Google Scholar
• MAIESE K, BONIECE IR, SKURAT K, WAGNER JA: Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. J. Neurosci. Res. (1993) 36(1):77–87.
   PubMed Web of Science ®Google Scholar
• CHEN HH, BURNETT JC, JR.: The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc. Assoc. Am. Physicians (1999) 111(5):406–416.
   Google Scholar
• RUTH P: Cyclic GMP-dependent protein kinases: understanding in vivo functions by gene targeting. Pharmacol. Ther. (1999) 82(2-3):355–372.
   PubMed Web of Science ®Google Scholar
• SCHOENBERG MH, MAYER JM, BEGER HG: Phospholi-pase A2-from basic research to clinical reality. Chirurg (1997) 68(10:1112–1118.
   PubMedGoogle Scholar
• •Offers new possibilities for early markers for severe inflam-mation and predicting systemic complications.
   Google Scholar